Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Divisional Update Highlights Consistent Program and Product Progress Across the Board

  • MINDCURE plans to schedule a pre-IND meeting with the FDA for its Desire Project during Q1 2022 with a subsequent Phase 2 trial to begin Q3 2022
  • The company expects that the GLP supply of ibogaine will be available for distribution to research partners in Q2 2022
  • Information on MC-106 and MC-808, an expansion of MINDCURE’s drug pipeline, will be released during Q2 2022

As a member of the Digital Therapeutics Alliance, Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) delivers digital therapeutics (“DTx”) that are evidence-based interventions driven by high-quality software to prevent, manage, and treat medical disorders or diseases. DTx can be used independently or with other medications, devices, or therapies, to optimize outcomes and patient care. MINDCURE is a leader in advanced proprietary technology and research centered around psychedelics and is currently advancing multiple programs and products to this end.

The attested progress and plans for the immediate future were detailed in an operational update regarding the strategic initiatives of the company’s operating segments – MINDCURE Research and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.